Wave Life Sciences Ltd. (1U5)
XMUN 
Summary
1U5 Chart
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences (NASDAQ:WVE) trades at $5.24, a step above its 52-week low of $5.01 and far beneath the 52-week high of $21.73.
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.31 per share a year ago.
Wave Life Sciences Ltd. (1U5) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Wave Life Sciences Ltd. ever had a stock split?
Wave Life Sciences Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Paul Bolno CEO | XMUN Exchange | SG9999014716 ISIN |
| US Country | 317 Employees | - Last Dividend | - Last Split | 11 Nov 2015 IPO Date |
Overview
Wave Life Sciences Ltd. is at the forefront of biotechnology, focusing on the design, development, and commercialization of revolutionary ribonucleic acid (RNA) medicines. Leveraging their proprietary PRISM discovery and drug development platform, the company is dedicated to transforming the treatment landscape for both rare and common disorders. This platform integrates versatile modalities, innovative chemistry, and advanced insights into human genetics to craft scientific breakthroughs. Established in 2012 and headquartered in Singapore, Wave Life Sciences is a clinical-stage company that embarks on strategic collaborations with industry giants like GlaxoSmithKline, Takeda Pharmaceutical Company Limited, and Asuragen, Inc., to enhance the reach and efficacy of its RNA therapeutics.
Products and Services
- WVE-006
- siRNA clinical candidate for Obesity and Metabolic Disorders
- WVE-N531
- WVE-003
An RNA editing oligonucleotide under development for treating alpha-1 antitrypsin deficiency. This innovative approach aims to directly modify the RNA responsible for the disorder, offering a potential new approach to treatment.
A specialized small interfering RNA (siRNA) therapeutic aimed at addressing obesity and other metabolic disorders. This candidate demonstrates the company's commitment to tackling prevalent, complex health issues through targeted RNA interference mechanisms.
An exon skipping oligonucleotide designed to treat Duchenne muscular dystrophy. This product reveals the potential of RNA-based therapies to correct genetic mutations and restore normal function, particularly in diseases caused by specific genetic errors.
An antisense silencing oligonucleotide targeting Huntington's disease (HD). By inhibiting the production of the harmful proteins that cause HD, WVE-003 represents a cutting-edge approach to treating this devastating neurodegenerative disorder.
